NKT
Business Services · Delaware, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
200 Powder Mill E 400 Road Bldg, Wilming...Phone Number
(302) 415-5127Website
www.nikangtx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
2
1
1
About NKT
NiKang Therapeutics is a clinical stage biotech company focused on discovering and developing innovative small molecules oncology medicines to help patients with unmet medical needs. Established in 2017, NiKang Therapeutics is headquartered in Delaware, United States.Explore more
NKT Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NKT your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if NKT had a recent Job posting/layoffs
Check if NKT has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when NKT launches new products
Check out if NKT is spiking on competitors!
NKT, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at NKT
Funding: Get notified immidiatlly once NKT has new funding data
Earning: See what the market has to say on NKT recently announced quarterly report
Recommended Actions
Find VP level buyers at NKT
Find more new buyers
Compare Similar Companies to NKT
Compare insights from companies similar to NKT, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NKT is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
NKT is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about NKT.
NKT financials insights
Gather financial insights about NKT, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$10M
2020
Debt
$150K
Series B
$50M
2021
Series C
$200M
NKT Tech Stack
A closer look at the technologies used by NKT
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Open Position
NKT News & Media
NiKang Therapeutics® Announces First Patient Dosed in a Phase 1b/2 Study of NKT2152 in Combination with Standard-of-Care in First-Line Regimen for Hepatocellular Carcinoma
WILMINGTON, Del.--(BUSINESS WIRE)--NiKang Therapeutics® Inc. (“NiKang”), a clinical-stage biotech company focused on developing innovative small molecule oncology medicines to bring transformative therapies to patients in need, today announced that the first patient has been dosed in the global randomized phase 1b/2 clinical study evaluating NKT2152, a highly potent, selective and orally bioavailable small molecule HIF2α inhibitor, in combination with standard-of-care regimen of atezolizumab (TNiKang Therapeutics® Presents Discovery of NKT3964, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2 PROTAC Degrader for Cancer Therapy, at the EORTC-NCI-AACR Symposium 2024
WILMINGTON, Del.--(BUSINESS WIRE)--NiKang Therapeutics® Inc. (“NiKang”) is a clinical stage biotech company focused on developing innovative small molecule oncology medicines to bring transformative therapies to patients in need. The company announced today the unveiling of NKT3964 at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (“Triple Meeting”) during a Poster Spotlight Session. The conference is being held October 23-25, 2024, in Barcelona, Spain. NKT3964 is a fNiKang Therapeutics® to Present Preliminary Results of Phase 1/2 Clinical Trial of NKT2152 in Patients with Previously Treated Advanced Clear Cell Renal Cell Carcinoma at ESMO 2024 Congress
WILMINGTON, Del.--(BUSINESS WIRE)--NiKang Therapeutics® Inc. (“NiKang”), a clinical-stage biotech company focused on developing innovative small molecule oncology medicines to bring transformative therapies to patients in need, today announced that preliminary data from its ongoing Phase 1/2 clinical trial evaluating NKT2152 for the treatment of previously treated advanced clear cell renal cell carcinoma (ccRCC) will be presented in an oral presentation at the European Society for Medical OncolNiKang Therapeutics Doses First Patient in a Phase 1/1b Study of NKT3447, an Oral, Selective Inhibitor of CDK2 Which Reduces Cyclin E Expression
WILMINGTON, Del.--(BUSINESS WIRE)--NiKang Therapeutics Inc. (“NiKang”) is a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs. The Company announced today that the first patient has been dosed in a phase 1/1b, open-label, first-in-human dose escalation and expansion study of single agent NKT3447, a small molecule that inhibits cyclin-dependent kinase 2 (CDK2). NKT3447 is designed to treat patients with can
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NKT
Sign Up For FreeTo access detailed company insights
NiKang Therapeutics is a clinical stage biotech company focused on discovering and developing innovative small molecules oncology medicines to help patients with unmet medical needs. Established in 2017, NiKang Therapeutics is headquartered in Delaware, United States.... Read More
